By Adriano Marchese
Enanta Pharmaceuticals said it saw positive results from its recent study evaluating a treatment for respiratory syncytial virus in newborns, also known as RSV.
The clinical-stage biotechnology company said Monday that topline results from the phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with RSV were positive.
RSV usually presents itself mildly, with people developing cold-like symptoms, but it is the leading cause of infant hospitalization in the U.S., according to the Centers for Disease Control and Prevention.
"Zelicapavir demonstrated an antiviral effect on both primary endpoints, as well as secondary virology endpoints," Chief Medical Officer Scott Rottinghaus said.
Enanta said it also saw a favorable safety profile for the drug over the initial five-day dosing period and through 23 days of follow-up.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 09, 2024 07:12 ET (12:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。